The Oncology Institute Stock Performance

TOIIW Stock  USD 0.11  0.02  18.15%   
Oncology Institute holds a performance score of 4 on a scale of zero to a hundred. The company holds a Beta of -4.48, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oncology Institute are expected to decrease by larger amounts. On the other hand, during market turmoil, Oncology Institute is expected to outperform it. Use Oncology Institute sortino ratio, as well as the relationship between the semi variance and rate of daily change , to analyze future returns on Oncology Institute.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in The Oncology Institute are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain forward indicators, Oncology Institute showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1
Is The Oncology Institute Inc. stock a safe buy before earnings - 2025 Growth vs Value Long-Term Growth Stock Strategies - newser.com
10/24/2025
2
Disposition of 590892 shares by M33 Growth I L.p. of Oncology Institute subject to Rule 16b-3
11/18/2025
3
A Mysterious Stock Has Rallied Over 950 percent This Year. Heres 1 Key Reason Why Investors Are Turning Bullish - The Motley Fool
11/21/2025
4
Acquisition by Johnson Karen Marie of 37037 shares of Oncology Institute subject to Rule 16b-3
11/24/2025
5
A Mysterious Stock Has Rallied Over 950 percent This Year. Heres 1 Key Reason Why Investors Are Turning Bullish - AOL.com
12/11/2025
6
Disposition of 13333 shares by Hively Brad of Oncology Institute at 3.7719 subject to Rule 16b-3
12/15/2025
7
Insider Trading
12/23/2025
8
Disposition of 247 shares by Robert Carter of Oncology Institute at 3.56 subject to Rule 16b-3
01/02/2026
9
For Oncology Institute Insiders, Selling US644k Of Shares Was A Smart Move - simplywall.st
01/07/2026
10
Cancer care group projects growth and first full year of adjusted profit - Stock Titan
01/12/2026
11
Acquisition by Hively Brad of 45280 shares of Oncology Institute at 1.0417 subject to Rule 16b-3
01/30/2026
12
Acquisition by Podnos Yale of 157088 shares of Oncology Institute subject to Rule 16b-3
02/02/2026
Begin Period Cash Flow33.5 M
Total Cashflows From Investing Activities46.2 M

Oncology Institute Relative Risk vs. Return Landscape

If you would invest  16.00  in The Oncology Institute on November 15, 2025 and sell it today you would lose (5.00) from holding The Oncology Institute or give up 31.25% of portfolio value over 90 days. The Oncology Institute is currently producing 1.0358% returns and takes up 19.5519% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Oncology, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Oncology Institute is expected to generate 25.17 times more return on investment than the market. However, the company is 25.17 times more volatile than its market benchmark. It trades about 0.05 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Oncology Institute Target Price Odds to finish over Current Price

The tendency of Oncology Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.11 90 days 0.11 
about 90.18
Based on a normal probability distribution, the odds of Oncology Institute to move above the current price in 90 days from now is about 90.18 (This The Oncology Institute probability density function shows the probability of Oncology Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon The Oncology Institute has a beta of -4.48. This usually implies as returns on its benchmark rise, returns on holding The Oncology Institute are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Oncology Institute is expected to outperform its benchmark. Moreover The Oncology Institute has an alpha of 1.4588, implying that it can generate a 1.46 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Oncology Institute Price Density   
       Price  

Predictive Modules for Oncology Institute

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as The Oncology Institute. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.0919.64
Details
Intrinsic
Valuation
LowRealHigh
0.000.119.65
Details

Oncology Institute Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Oncology Institute is not an exception. The market had few large corrections towards the Oncology Institute's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold The Oncology Institute, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oncology Institute within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.46
β
Beta against Dow Jones-4.48
σ
Overall volatility
0.04
Ir
Information ratio 0.06

Oncology Institute Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncology Institute for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for The Oncology Institute can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Oncology Institute is way too risky over 90 days horizon
Oncology Institute has some characteristics of a very speculative penny stock
Oncology Institute appears to be risky and price may revert if volatility continues
Oncology Institute has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 393.41 M. Net Loss for the year was (53.01 M) with profit before overhead, payroll, taxes, and interest of 68.31 M.
The Oncology Institute has accumulated about 15.17 M in cash with (26.54 M) of positive cash flow from operations.
Latest headline from news.google.com: Acquisition by Podnos Yale of 157088 shares of Oncology Institute subject to Rule 16b-3

Oncology Institute Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncology Stock often depends not only on the future outlook of the current and potential Oncology Institute's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncology Institute's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding75 M
Cash And Short Term Investments49.7 M

Oncology Institute Fundamentals Growth

Oncology Stock prices reflect investors' perceptions of the future prospects and financial health of Oncology Institute, and Oncology Institute fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncology Stock performance.

About Oncology Institute Performance

Evaluating Oncology Institute's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Oncology Institute has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncology Institute has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 9.72  11.05 
Return On Tangible Assets(0.49)(0.52)
Return On Capital Employed(0.57)(0.60)
Return On Assets(0.43)(0.41)
Return On Equity(20.72)(19.68)

Things to note about The Oncology Institute performance evaluation

Checking the ongoing alerts about Oncology Institute for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for The Oncology Institute help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Oncology Institute is way too risky over 90 days horizon
Oncology Institute has some characteristics of a very speculative penny stock
Oncology Institute appears to be risky and price may revert if volatility continues
Oncology Institute has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 393.41 M. Net Loss for the year was (53.01 M) with profit before overhead, payroll, taxes, and interest of 68.31 M.
The Oncology Institute has accumulated about 15.17 M in cash with (26.54 M) of positive cash flow from operations.
Latest headline from news.google.com: Acquisition by Podnos Yale of 157088 shares of Oncology Institute subject to Rule 16b-3
Evaluating Oncology Institute's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Oncology Institute's stock performance include:
  • Analyzing Oncology Institute's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncology Institute's stock is overvalued or undervalued compared to its peers.
  • Examining Oncology Institute's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Oncology Institute's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncology Institute's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Oncology Institute's stock. These opinions can provide insight into Oncology Institute's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Oncology Institute's stock performance is not an exact science, and many factors can impact Oncology Institute's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Oncology Stock Analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.